Trial reportBone marrow transplantation2026
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.
Trial report in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07232953 (Prospective Phase II Study on Safety and Efficacy of Fludarabine Plus Treosulfan), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Phase II Study on Safety and Efficacy of Fludarabine Plus Treosulfan (14g) (FT14) Conditioning Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Acute Myeloid Leukemia (AML) Patients (≥40 <65years) (FT14-Trial)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidences supporting the use of myeloablative-dose Treosulfan combined with Fludarabine remain largely retrospective, with outdated prospective studies available. In this phase II multicenter prospective trial, we evaluated the safety and efficacy of FT14 conditioning regimen in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in first complete remission.(EudraCT Number:2021-006515-28; Clinical trial number NCT07232953). The study was designed to provide a non-inferior alternative to standard busulfan-containing regimens, which would enable effective transplantation while minimizing toxicity. The primary objective was 1-year Leukemia-free survival (LFS). In total, 82 patients were enrolled in the study with a median follow up of 19.7 months; donor used were matched sibling in 22, matched unrelated 52 and mismatched unrelated in 8 cases, respectively. LFS at 180-day and 365-day were 87.8% and 81.7%, respectively. Cumulative incidence of relapse at 1 year after allo-HSCT was 14.9% with mean time to relapse of 5.6 months. Also, FT14 regimen provided an excellent safety with nearly absent NRM, no cases of septic death, and no cases of primary graft failure. Our study supports the use of FT14 as effective myeloablative conditioning regimen for AML patients aged 40-65 y in first complete remission, especially in patients for whom busulfan based conditioning regimens poses excessive toxic risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.